SANUWAVE Health Inc.

NASDAQ: SNWV · Real-Time Price · USD
26.21
-1.97 (-6.99%)
At close: May 30, 2025, 3:59 PM
26.20
-0.04%
After-hours: May 30, 2025, 04:04 PM EDT

Company Description

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally.

Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures.

The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers.

Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration.

The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions.

In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures.

The company was founded in 2005 and is headquartered in Suwanee, Georgia.

SANUWAVE Health Inc.
SANUWAVE Health Inc. logo
Country United States
IPO Date Sep 30, 2009
Industry Medical - Devices
Sector Healthcare
Employees 46
CEO Morgan C. Frank

Contact Details

Address:
3360 Martin Farm Road
Suwanee, Georgia
United States
Website https://www.sanuwave.com

Stock Details

Ticker Symbol SNWV
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001417663
CUSIP Number 80303D107
ISIN Number US80303D1072
Employer ID 20-1176000
SIC Code 3841

Key Executives

Name Position
Morgan C. Frank Chief Executive Officer & Chairman
Peter Sorensen Chief Financial Officer
Peter Stegagno Chief Operating Officer
Andrew Walko President
Dr. Iulian Cioanta Ph.D. Chief Science & Technology Officer
Nanci Gilmore Chief Commercial Officer
Timothy Wern Executive Vice President of Sales - U.S. Wound

Latest SEC Filings

Date Type Title
May 29, 2025 4 Filing
May 29, 2025 3 Filing
May 29, 2025 8-K Current Report
May 21, 2025 8-K/A [Amend] Current Report
May 16, 2025 4 Filing
May 15, 2025 8-K Current Report
May 15, 2025 SCHEDULE 13G/A [Amend] Filing
May 09, 2025 SCHEDULE 13G/A [Amend] Filing
May 09, 2025 8-K Current Report
May 08, 2025 10-Q Quarterly Report